Welcome To Taro International

Taro Pharmaceutical Industries is a research-based pharmaceutical manufacturer publicly listed in the New York Stock Exchange.

The company develops, manufactures, markets, and distributes high-quality generics, branded Rx, and OTC products.

The company has more than 2oo products, in a variety of therapeutic areas principally dermatology, analgesics, gastro, CNS, cardiology.

Taro Pharmaceutical Industries is reported to be on steady growth since 2008. Its revenues have increased from $327 million to over $850 on 2014 , and at the same time, its earnings per share have been increasing from $0.76 to an estimated $13.00 during this period.

R&D - Taro develops high-quality, proprietary and off-patent pharmaceuticals ,prescription , over-the counter products including tablets, capsules, suspensions, solutions, creams, foams and ointments.

API - Taro’s Active Pharmaceutical Ingredients (API) Division, founded in Israel in 1961, provides Taro Pharmaceutical Industries with vertical integration from the API to finished dosage formulations and is also a source of high quality APIs to markets worldwide

FDF - Taro currently markets its products in over 20 countries with 300+ registered products mainly in the US ,Israel and Canada and has Key centers in the United States, Canada, and Israel with state-of-the-art facilities.

In addition to all of the above, Taro represents several major pharmaceutical companies in Israel. Since business development is an important part of our company and its growth, we are always interested in learning about new opportunities. To learn more click here

Click image to enlarge

Press Releases

October 30, 2017
Taro to Announce Second Quarter Results on November 7, 2017

August 08, 2017
Taro Provides Results for Quarter Ended June 2017

June 22, 2017
Taro Annual Report on Form 20-F Available for Fiscal Year Ended March 31, 2017

May 22, 2017
Taro Provides Results for Year Ended March 31, 2017

December 23, 2016
Taro Announces Sale of U.S. Rights to Keveyis® to Strongbridge Biopharma plc

December 01, 2016
Taro Announces Appointment of Interim CEO

November 23, 2016
Taro Announces New $250 Million Share Repurchase Authorization

July 06, 2016
Taro CEO Kal Sundaram to Return to Sun Pharma Headquarters by the End of 2016

June 21, 2016
Taro Announces Resignation of Chief Financial Officer

Privacy Statement   |   Terms of Use   |   Safe Harbor Statement